William K. Kelly, DO, discusses the next steps with the combination of radium-223 dichloride and niraparib in metastatic castration-resistant prostate cancer.
William K. Kelly, DO
Advertisement
Articles by William K. Kelly, DO
William K. Kelly, DO, discusses the design of a phase 1B dose-finding trial that evaluated the combination of radium-223 dichloride and niraparib in metastatic castration-resistant prostate cancer.
William K. Kelly, DO, discusses results from a phase 1b dose-finding study evaluating the combination of radium-223 dichloride (Xofigo) plus niraparib (Zejula) in patients with metastatic castration-resistant prostate cancer.
Advertisement
Latest Updated Articles
Dr. Kelly on Identifying Optimal Dose of Radium-223 and Niraparib in mCRPCPublished: June 19th 2020 | Updated:
Dr. Kelly on Efficacy of Radium-223 Dichloride and Niraparib in Patients With mCRPCPublished: June 10th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5